^
Association details:
| Biomarker: | KMT2C mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.
Published date:
05/19/2021
Excerpt:
Higher frequency of KMT2C mutation (missense and splicing, p = 0.040) were observed in response group...Combination of PD-1 inhibitor with lenvatinib as conversion therapy could benefit unresectable advanced HCC patients…
